Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process
Mandate

Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process

August 17, 2018

In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total value of approximately SEK 178 million.

Following the transaction, Industrifonden holds approximately 23.67% of the shares in Oncopeptides.
 
Vinge’s team consisted of Dain Hård Nevonen, Rikard Lindahl and Sofie Bjärtun.

Related

Vinge advises Pricer AB in connection with its issuance of senior unsecured bonds and early redemption

 Vinge advises Pricer AB (publ) in connection with its issuance of floating rate senior unsecured bonds of SEK 300 million within a framework of SEK 500 million and early redemption of existing bonds.
December 10, 2024

Vinge advises Carasent in connection with the listing on Nasdaq Stockholm

 Vinge advises Carasent AB (publ) in connection with the listing on Nasdaq Stockholm. The listing is made through a reverse cross-border merger, whereby Carasent AB takes over Carasent ASA, previously listed on Oslo Stock Exchange.
December 09, 2024

Vinge has advised Apotea in connection with its listing on Nasdaq Stockholm

 Vinge has advised Apotea AB (publ) (“Apotea”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on November 26, 2024 and the first day of trading is December 6, 2024.
December 06, 2024